Vyanka Redenbaugh

Introduction Myelin oligodendrocyte glycoprotein antibody (MOG-IgG) was identified as a biomarker of central nervous system (CNS) demyelinating disease in 2007.1 More recently, MOG-IgG-associated disease (MOGAD) was recognized as a separate disease, distinct from multiple sclerosis (MS) and aquaporin-4-IgG positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD) with international diagnostic criteria proposed in 2023.2 MOGAD is commonly associated with optic neuritis (ON), acute...

Introduction The spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has expanded with newer phenotypes being identified.1 Recent studies have also reported the involvement of peripheral nervous system (PNS) in association with MOG-IgG, including isolated neuropathies.2, 3 However, caution is needed as low-positive MOG-IgG can be encountered occasionally in disease controls.4 Herein we evaluate the involvement of PNS in a large cohort of MOG-IgG1 seropositive...